563 related articles for article (PubMed ID: 20435235)
1. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism.
Tennezé L; Tarral E; Ducloux N; Funck-Brentano C
Clin Pharmacol Ther; 2002 Aug; 72(2):112-22. PubMed ID: 12189358
[TBL] [Abstract][Full Text] [Related]
3. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers.
Kim TE; Kim BH; Kim J; Kim KP; Yi S; Shin HS; Lee YO; Lee KH; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Oct; 31(10):2249-57. PubMed ID: 19922896
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
Wang Z; Grasela DM; Krishna G
Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.
Lim KS; Cho JY; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Shin SG; Yu KS
Br J Clin Pharmacol; 2008 Nov; 66(5):660-6. PubMed ID: 18754843
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
10. Dispersion of the corrected QT and JT interval in the electrocardiogram of alcoholic patients.
Corović N; Duraković Z; Misigoj-Duraković M
Alcohol Clin Exp Res; 2006 Jan; 30(1):150-4. PubMed ID: 16433743
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
12. Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects.
Ayalasomayajula S; Yeh CM; Vaidyanathan S; Flannery B; Dieterich HA; Howard D; Bedigian MP; Dole WP
J Clin Pharmacol; 2008 Jul; 48(7):799-811. PubMed ID: 18490495
[TBL] [Abstract][Full Text] [Related]
13. Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea.
Kim BH; Yi S; Kim J; Lim KS; Kim KP; Lee B; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Jun; 31(6):1234-43. PubMed ID: 19695390
[TBL] [Abstract][Full Text] [Related]
14. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
[TBL] [Abstract][Full Text] [Related]
15. Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects.
Hu M; Yang YL; Fok BS; Chan SW; Chu TT; Poon EW; Yin OQ; Lee VH; Tomlinson B
Drug Metabol Drug Interact; 2012 Jan; 27(1):33-9. PubMed ID: 22718623
[TBL] [Abstract][Full Text] [Related]
16. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
19. A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.
Mansbach RS; Ludington E; Rogowski R; Kittrelle JP; Jochelson P
Clin Ther; 2011 Jul; 33(7):851-62. PubMed ID: 21722958
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.
Doki K; Homma M; Kuga K; Aonuma K; Kohda Y
Pharmacogenet Genomics; 2012 Nov; 22(11):777-83. PubMed ID: 22941032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
